Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults


Quigley, MA; Mwinga, A; Hosp, M; Lisse, I; Fuchs, D; Porter, JDH; Godfrey-Faussett, P; (2001) Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS (London, England), 15 (2). pp. 215-22. ISSN 0269-9370 DOI: https://doi.org/10.1097/00002030-200101260-00011

Full text not available from this repository. (Request a copy)

Abstract

OBJECTIVE: To determine the long-term effect of preventive therapy (PT) for tuberculosis on the rates of tuberculosis, mortality and HIV progression. METHODS: In a randomized controlled trial, 1053 HIV-positive Zambian adults received isoniazid (H) for 6 months, rifampicin plus pyrazinamide (RZ) for 3 months, or a placebo. CD4 percentage, neopterin, absolute lymphocyte count and haemoglobin were measured from enrolment (absolute CD4 cell counts from 12 months after enrolment). Because PT reduced the incidence of tuberculosis, eligible placebo subjects were offered H. Here, tuberculosis and mortality rates are compared in the three original arms (intention to treat) using data beyond the end of the trial (average follow-up 3 years; maximum 7 years). RESULTS: There were 102 cases of tuberculosis and 281 deaths (rates 3.6 and 9.0/100 person-years, respectively). There was no significant difference between the tuberculosis rates in the H and RZ groups at any time. The effect of H/RZ on tuberculosis diminished over time (P = 0.011) but the cumulative risk of tuberculosis in the first 2.5 years was significantly lower in the H/RZ group than the placebo group (rate ratio 0.55; 95% confidence interval 0.32-0.93; P = 0.028). There was no significant effect of PT on mortality or progression markers. Tuberculosis was associated with an increased mortality (adjusted rate ratio 1.96; 95% confidence interval 1.21-3.18; P = 0.006). CONCLUSIONS: Both PT regimens protect against tuberculosis for at least 2.5 years but appear to have no effect on HIV progression or mortality. These results may be used in cost-effectiveness models of PT.

Item Type: Article
Keywords: AIDS-Related Opportunistic, Infections/immunology/mortality/physiopathology/*prevention & control, Adult, Antitubercular Agents/*pharmacology, CD4 Lymphocyte Count, Cohort Studies, Disease Progression, Female, Follow-Up Studies, HIV Infections/immunology/physiopathology, Human, Isoniazid/*pharmacology, Male, Pyrazinamide/*pharmacology, Rifampin/*pharmacology, Support, Non-U.S. Gov't, Time Factors, Treatment Outcome, Tuberculosis/immunology/mortality/physiopathology/*prevention & control, Zambia, AIDS-Related Opportunistic Infections, immunology, mortality, physiopathology, prevention & control, Adult, Antitubercular Agents, pharmacology, CD4 Lymphocyte Count, Cohort Studies, Disease Progression, Female, Follow-Up Studies, HIV Infections, immunology, physiopathology, Human, Isoniazid, pharmacology, Male, Pyrazinamide, pharmacology, Rifampin, pharmacology, Support, Non-U.S. Gov't, Time Factors, Treatment Outcome, Tuberculosis, immunology, mortality, physiopathology, prevention & control, Zambia
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
PubMed ID: 11216930
Web of Science ID: 166822700014
URI: http://researchonline.lshtm.ac.uk/id/eprint/16671

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
324Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item